FindTrial
Sign In

Therapeutic effect of an immunosupp-ressive agent, mizoribine in patients with the progression of renal failure in diabetic nephropathy

Therapeutic effect of an immunosupp-ressive agent, mizoribine in patients with the progression of renal failure in diabetic nephropathy - Therapeutic effect of mizoribine in patients with diabetic nephropathy

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001824
Enrollment
40
Registered
2009-03-31
Start date
2008-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Conventional therapy for diabetic nephropathy Conventional therapy for diabetic nephropathy + MZR

Sponsors

Okayama University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diabetic nephropathy patients with retinopathy.Patients who had diabetes mellitus for at least 5 years.Urinary protein excretion of over 1.0g/dayThe mean gradient of 3 or more of the reciprocal serum creatinine levels before 6 months is below -0.005

Exclusion criteria

Exclusion criteria: Patients who is received cortico- steroid or immunosuppressant.Patients whose blood pressure is over 160/100mmHg or whose HbA1c is over 10.0%.Patients with a hypersensitivity to MZR.Patients whose WBC are under 3000/mm3.Pregnant or nursing women.

Design outcomes

Primary

MeasureTime frame
The mean gradient of the reciprocal serum creatinine levels between MZR treated and non-treated.—

Secondary

MeasureTime frame
The frequency of lethal event and non-lethal event.Lethal event: myocardial infarction(angina pectoris)Non-lethal event: state of renal failure increasing to 5.00mg/dl or more of s-Cr. level.—

Countries

Japan

Contacts

Public ContactKen-ichi Shikata

Okayama University Nephrology Diabetology and Endocrinology

086-223-7151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026